Imagyn sells minimal access line for $34 million:
This article was originally published in Clinica
Imagyn Medical Technologies has completed the sale of its minimal access surgery product line to CONMED for $33.9 million. This is based on CONMED's closing share price of $26.10 on July 6. This compares with a transaction value of $29.7 million when the deal was announced.
You may also be interested in...
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.